88 related articles for article (PubMed ID: 22825036)
1. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer.
Fard-Esfahani A; Farzanefar S; Fallahi B; Beiki D; Saghari M; Emami-Ardekani A; Majdi M; Eftekhari M
Nucl Med Commun; 2012 Oct; 33(10):1077-80. PubMed ID: 22825036
[TBL] [Abstract][Full Text] [Related]
2. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer.
Sakahara H; Yamashita S; Suzuki K; Imai M; Kosugi T
Ann Nucl Med; 2007 Nov; 21(9):525-7. PubMed ID: 18030585
[TBL] [Abstract][Full Text] [Related]
3. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma.
Kloos RT; Duvuuri V; Jhiang SM; Cahill KV; Foster JA; Burns JA
J Clin Endocrinol Metab; 2002 Dec; 87(12):5817-20. PubMed ID: 12466391
[TBL] [Abstract][Full Text] [Related]
4. [Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma].
Fonseca FL; Lunardelli P; Matayoshi S
Arq Bras Oftalmol; 2012; 75(2):97-100. PubMed ID: 22760799
[TBL] [Abstract][Full Text] [Related]
5. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma.
Fard-Esfahani A; Mirshekarpour H; Fallahi B; Eftekhari M; Saghari M; Beiki D; Ansari-Gilani K; Takavar A
Clin Nucl Med; 2007 Sep; 32(9):696-9. PubMed ID: 17710021
[TBL] [Abstract][Full Text] [Related]
6. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study.
Zettinig G; Hanselmayer G; Fueger BJ; Hofmann A; Pirich C; Nepp J; Dudczak R
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1428-32. PubMed ID: 12397459
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic dacryocystorhinostomy following radioactive iodine thyroid ablation.
Van Tassel SH; Segal KL; Hsu NM; Kacker A; Lelli GJ
Orbit; 2017 Apr; 36(2):59-63. PubMed ID: 28388347
[TBL] [Abstract][Full Text] [Related]
8. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
9. Relationship between radioactive iodine therapy for thyroid carcinoma and nasolacrimal drainage system obstruction.
Cetinkaya A; Kersten RC
Ophthalmic Plast Reconstr Surg; 2007; 23(6):496. PubMed ID: 18030131
[No Abstract] [Full Text] [Related]
10. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated With Radioactive Iodine Therapy-Acquired Nasolacrimal Duct Obstruction.
Lee IT; Chen W; Chen Q; Cole HA; Bischoff LA; Jessop AC; Sobel RK
Endocr Pract; 2022 Dec; 28(12):1210-1215. PubMed ID: 35970353
[TBL] [Abstract][Full Text] [Related]
12. Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following I-131 therapy.
Savage MW; Sobel RK; Hoffman HT; Carter KD; Finkelstein MW; Shriver EM
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e50-2. PubMed ID: 24836449
[TBL] [Abstract][Full Text] [Related]
13. [Changes in the blood picture after radioiodine therapy of thyroid cancer].
Grünwald F; Schomburg A; Menzel C; Steinecker S; Späth G; Bockisch A; Fimmers R; Hotze AL; Biersack HJ
Med Klin (Munich); 1994 Oct; 89(10):522-8. PubMed ID: 7808352
[TBL] [Abstract][Full Text] [Related]
14. Nasolacrimal obstruction secondary to I(131) therapy.
Burns JA; Morgenstern KE; Cahill KV; Foster JA; Jhiang SM; Kloos RT
Ophthalmic Plast Reconstr Surg; 2004 Mar; 20(2):126-9. PubMed ID: 15083081
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Demographic Characteristics of Tearing in Patients after Radioiodine Ablation for Differentiated Thyroid Cancer.
Yartsev VD; Solodkiy VA; Fomin DK; Borisenko TE; Atkova EL
Curr Eye Res; 2021 Sep; 46(9):1320-1324. PubMed ID: 33455422
[No Abstract] [Full Text] [Related]
16. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
17. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
18. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma.
Shepler TR; Sherman SI; Faustina MM; Busaidy NL; Ahmadi MA; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2003 Nov; 19(6):479-81. PubMed ID: 14625496
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of nasolacrimal duct obstruction after iodine therapy in differentiated thyroid cancer patients.
Li N; Zhang W
Ear Nose Throat J; 2023 Apr; ():1455613231170088. PubMed ID: 37070248
[TBL] [Abstract][Full Text] [Related]
20. Lacrimal System Obstruction After Radioiodine Therapy in Differentiated Thyroid Carcinomas: A Prospective Comparative Study.
da Fonseca FL; Yamanaka PK; Kato JM; Matayoshi S
Thyroid; 2016 Dec; 26(12):1761-1767. PubMed ID: 27565021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
